Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Observational, Bi-directional (Prospective and Retrospective) Study for Patients With Newly Diagnosed Ovarian Cancer Stages IA to IVB, or Persistent or Recurrent Disease From January 2021; Irrespective of Histology
Observational, Bi-directional (Prospective and Retrospective) Study for Patients With Newly Diagnosed Ovarian Cancer Stages IA to IVB, or Persistent or Recurrent Disease From January 2021; Irrespective of Histology

NCT07167433

RecruitingN/A

Sponsor: AstraZeneca

Conditions: Ovarian Cancer

Countries: Brazil

The findings from this study have the potential to serve as a foundation for evaluating the current practices related to surgical procedures, systemic therapies, hyperthermic intraperitoneal chemotherapy, and referrals to geneticists for OC patients. By identifying the strengths and weaknesses of the existing care, this project intends to generate valuable insights that can lead to the implementation of quality parameters for the treatment of ovarian cancer in the country.

Eligibility overview

Sex: FEMALE

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:

* Patients ≥18 years old;
* Newly diagnosed ovarian cancer stages IA to IVB, or persistent or recurrent disease from January 2021;
* Irrespective of histology

Exclusion Criteria:

* Borderline tumors;
* Pregnancy;
* Synchronous tumor or second primary in the last 5 years (except thyroid cancer and non-melanoma skin cancer);
Locations (15)
  • Barretos/SP, Brazil
  • Belo Horizonte/MG, Brazil
  • Bras lia/DF, Brazil
  • Curitiba/PR, Brazil
  • Goi nia/GO, Brazil
  • Joao Pessoa/PB, Brazil
  • Natal/RN, Brazil
  • Porto Alegre/RS, Brazil
  • Porto Alegre/RS, Brazil
  • Recife/PE, Brazil
  • Rio Branco/AC, Brazil
  • Rio de Janeiro/RJ, Brazil
  • S O Jose Dos Campos/SP, Brazil
  • S O Paulo/SP, Brazil
  • Salvador/BA, Brazil